Clinical Trial Update: Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of three thalidomide doses for relapsed/refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED